Kailera Therapeutics is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.
Total raised: $400M
Investors 1
| Date | Name | Website |
| 04.10.2024 | Bain Capit... | baincapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.10.2024 | Series A | $400M | - |
Mentions in press and media 3
| Date | Title | Description |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 01.10.2024 | Kailera launches with $400M series A and clutch of Chinese obesity drugs | Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China and $400 million in series A funds. The Massachusetts- and California-based biotech is led by former Cerevel Therap... |
| - | Kailera Therapeutics | “Kailera is advancing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for obesity and related conditions.” |